Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-too-familiar routine of meetings, deadlines, and the like has returned with a vengeance.
You knew this would happen, yes? To cope, we are relying, as always, on a cuppa stimulation.
Our choice today is honeybush vanilla turmeric. Feel free to join us.
Remember, no prescription is required. Meanwhile, here are some tidbits to help you along.
Best of luck accomplishing your goals today, and, of course, do keep in touch. … Detailed study data for a pancreatic cancer treatment from Revolution Medicines confirmed what was previously announced in April by the company in a press release , STAT tells us.
Patients with advanced pancreatic cancer who received daraxonrasib as a second-line treatment achieved a median overall survival of 13.2 months, compared to 6.7 months for patients offered standard chemotherapy. Statistically, the drug reduced the risk of death by 60% compared with chemotherapy.
STAT News published a clinical update in Research Highlights on 01 Jun 2026.
The item focuses on STAT+: Pharmalittle: We’re reading about pancreatic and lung cancer drugs, China biotech growth, and more.
Review the original article for the full source wording and details.